Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-10b-5p inhibitor
- Development stage
- Preclinical
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous, Intratumoral, Intraperitoneal, Intrathecal, Intravitreal
01
Overview
miR-10b-5p inhibitor refers to a class of synthetic antisense oligonucleotides (antimiRs or antagomiRs) designed to bind and neutralize the microRNA miR-10b-5p. In various cancers, miR-10b-5p acts as an oncomiR, promoting tumor initiation, progression, and metastasis by downregulating tumor suppressor genes such as PTEN, HOXD10, and TET2. In glioblastoma (GBM), miR-10b-5p is highly expressed and correlates with poor prognosis; its inhibition has been shown to increase 5-hydroxymethylcytosine (5hmC) levels and inhibit tumor propagation in xenograft models. While widely used as a research tool and commercially available from reagent suppliers, there is currently no specific clinical-stage drug candidate or proprietary pharmaceutical program associated with this generic name.
- Other names
- antimiR-10b-5pantimiR10b-5pantimiR 10b-5pantagomiR-10b-5pantagomiR10b-5pantagomiR 10b-5pmiR-10b-5p antagomirmiR10b-5p antagomirmiR 10b-5p antagomir
02
Targets
miR-10b-5p (MicroRNA 10b-5p)
Beyond the preview
Go deeper on miR-10b-5p inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-10b-5p inhibitor.